Exhibit 99.1

Corporate Presentation June 2016

Safe Harborstatement Forward-Looking StatementsThis presentation contains certain statements that may be deemed to be “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended.Forward looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development and clinical trials; the timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; the degree of clinical utility of our products, particularly in specific patient populations; our ability to develop commercial functions; expectations regarding product launch and revenue; our results of operations, cash needs, and spending of the proceeds from this offering; financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us. As a result, actual results may differ materially from any financial outlooks stated herein. We may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “targets,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, may differ materially from the forward-looking statements contained in this presentation as a result of a variety of factors including but not limited to those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company’s product candidate and those risks and uncertainties associated with the protection of the Company’s intellectual property rights. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. This document is not intended to be and is not an advertisement for any securities of the Company. For a more complete discussion of the risk factors affecting our business, please refer to our Annual Report on Form 20-F filed on March 15, 2016, with the United States Securities and Exchange Commission which is available on its website at http://www.sec.gov. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. We undertake no obligation to update, amend or clarify such statements to reflect new information or events or circumstances occurring after the date of this presentation or to reflect the occurrence of unanticipated events. This information does not provide an analysis of the Company's financial position and is not a solicitation to purchase or sell securities of the Company. You should independently investigate and fully understand all risks before investing in the Company. 2

OurMission 3 A New Vision for Colorectal Cancer Prevention By removing barriers, changing perceptions, & increasing willingness for screening

About Check-Cap 4 Technology Ingestible X-ray scanning capsule Tracking control and data collection unitImage processing and viewing Clinical Trials $ 50mn raised Nasdaq: CHEK Ongoing in IsraelPlan to initiate U.S. pivotal trial in 2018 GE, Fosun Pharma,Pontifax Founded – 2005, Employees – 58 Located – Israel, Boston Clinical-Stage Medical Diagnostics Focused on CRC Screening

Colorectal Cancer a major public health problem 5 137k50k Source: American Cancer Society World Health Organization J Natl Cancer Inst. 2011; 103:1-12 (Mariotto) 134k49k 471k228k 253k139k 113k48k 1.36m694k Annual new cases world-wide -Annual deaths world-wide - Second leading cause of cancer deaths in U.S. Treatment costs projected to be >$17B in 2020

Colorectal Cancer highly preventable 6 Small Adenomatous Polyp (< 1cm) Cancer Screening can find polyps that can be removed before they turn into cancer Source: Gastro 1997;112:594-692 (Winawer) ACS recommendations for colorectal cancer early detection Photos: WEO Atlas Precancerous phase, readily detectable by structural examinations of the colon Asymptomatic patient Cancer patient ~10 years

Source: AGA Institute Guidelines for the Early Detection of Colorectal Cancer and Adenomatous Polyps Gastroenterology 2008; 134: 1570-1595 (Levin) ACS recommendations for colorectal cancer early detection CRC screening testscancer prevention and cancer detection 7 Colonoscopy, Sigmoidoscopy,CT Colonography Preventing colon cancer should be a major reason for getting tested Primary Aim:Detection of early-stage CRCCRC prevention by detection/removal of adenomas Prevention Primary Aim:Detection of early-stage CRC Detection gFOBTFITStool DNA

U.S screening ratesand the national goal 8 Source: CDC NHIS Survey results MMWR 2015 CA Cancer J Clin 2014;64:104-17 (Seigel) 2000 2010 2013 2018 80% 59% 35% goal Screening rates Significant declines in colorectal cancer incidence have been attributed to screening ages 50-75 58%

Perceptions and Barriers screening colonoscopy 9 Bowel Prep Restricted diet Sedation Pre-test fasting Fear of pain and discomfort Feeling of vulnerability Embarrassment A significant majority judged bowel preparation to be the worst part of the process, and the main barrier Patient Education and Counseling 2012;86:137-146 (McLachlan) Risk Procedural Personal

Removal of prepmay increase screening rates 10 15% 32% 21% 13% 11% 8% 86% of respondents would be much or somewhat more likely to undergo screening if laxative prep were to be removed. Source: Mayo Clinic Proc. 2007;82(6):666-671 (Beebe)

Check-CapSystem Ingestible scanning capsule 1 Capsule Positioning System - Biocompatible patch worn on patient's back for tracking capsule and recording data 2 3D colon imageviewer 3 Imaging Data + Positioning Data Data upload The Check-Cap System is not available for sale or clinical use in any jurisdiction. 11

Ultra-low dose X-ray scanning capsule 12 Patented technology detects photons XRF CMT from Compton Back-scattering and X-Ray Fluorescence As the capsule moves naturally, it scans the inner lining of the colon in a 360 degree arc, scanning only when in motion Patients drink a small amount of contrast agent (~1 TBP) with each meal during capsule passage

Patientscontinue their daily routine 13 As the capsule travels naturally, it transmits scanning and location Data to the Capsule Positioning System, mapping the structures of the internal colon. The capsule is excreted naturally and the patient is notified. Capsule route in colon Capsule Positioning System CPS Image for illustration only 1-5 days capsule passage

Physician reviewof clinical images 14 Image taken during colonoscopy of a 20-30mm polyp

Clinical datageneration 15 75 patients 2010 Capsule motility Germany/Israel Israel Israel/EU 1st clinical scanning capsule Source: Gut. 2016 Mar;65(3):371-3 (Gluck)

16 Case studypolyp in the sigmoid colon Fillet-typeprocessing Tube-type processing Image taken during screening colonoscopy of a 20mm polyp on a large stem in the sigmoid colon A section of the sigmoid colon where a polyp was located A 3D map of the colon as captured by the system A/P view

17 Case studypolyp in the ascending colon Fillet-typeprocessing Tube-type processing Image taken during colonoscopy of a 4mm sessile polyp on a haustra in the ascending colon A section of the ascending colon where a polyp was located A 3D map of the colon as captured by the system

Compelling market opportunity 18 $4B annual U. S. market opportunity** Source: * - population between ages 50-84 at average risk, U.S. Census Bureau, Pop. Division, 2014, company estimates ** - For patients screened once every 5 years at average Check-Cap System price of $600 J Clin Gastroenterol 2014 Jan;48(1):52-4 (Chatrath) Potential U.S. screening population of 84M* 575MPopulation age +50 at average risk*

Intellectual Property robust portfolio 19 Core patents granted in major jurisdictions 20 granted, 3 allowed, and 35 pending worldwide including the U.S. PTO, European Patent Organization, China, Japan, & India covering the core technology: Intra-Lumen Polyp Detection – system and method for an ingestible capsule with an X-ray source not requiring laxative preparationMeasurement of distance between capsule and colon walla method not requiring laxative preparation

Management 20 Bill Densel CEO 23 years of healthcare industry experience, including CEO of Beacon Endoscopic, CEO of Dune Medical, Cytyc/Hologic, Boston Scientific, Genzyme Biosurgery. Dr. Yoav KimchyFounder & CTO 12 years of executive R&D experience, including Vice President of R&D at V-Target Ltd. and Director of Cardiovascular Research at Impulse Dynamics Ltd. Alex Ovadia COO 12 years of experience as Global R&D Director, managing complex system projects at Philips Healthcare. 11 years of development management at Elbit Sytems. Lior Torem CFO Chief Financial Officer experience in both private and public companies. CFO at Superfish, Inc. Vice President of Finance at Actelis Networks, Inc. Dr. Walt Robb Steve Hanley Yuval Yanai Dr. Mary Jo Gorman XQ LinTomer Kariv Bill Densel BOD

Financial & Corporate summary 21 $11.7 million cash as of March 31, 2016 Financial Position • US IPO: February 2015• Traded on the NASDAQ: CHEK• Warrants traded on the NASDAQ: CHEKW• 12.2 million ordinary shares outstanding• Affiliate ownership: 21% Capital Structure

Targetmilestones 22 * Capital and strategic partner dependent Design release and transfer to productionComplete multi-center clinical study Data release from multi-center clinical studyCE Mark submission U.S Pilot Trial initiation H216 H117 01/08 U.S. Pivotal Trial initiation EU Post Market Study initiation Commercial launch EU* H217 H118 Pre-Submission meeting with FDA

Investment highlights 23

A New Vision For Colorectal Cancer Prevention